cryopyrin-associated periodic syndromes

cryopyrin-associated periodic syndromes

A range of autoinflammatory disorders—e.g., familial cold autoinflammatory syndrome (FCAS, aka familial cold-induced urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (NOMID, aka chronic infantile neurologic cutaneous and articular syndrome [CINCA])—which share many clinical features (e.g., fever, rash, joint pain, conjunctivitis, headaches, general malaise).

Management
Monoclonal antibodies against IL 1 beta (e.g., canakinumab), other IL-1 binding proteins (e.g., rilonacept), or IL-1 receptor antagonist (e.g., anakinra).
Mentioned in ?
References in periodicals archive ?
Cryopyrin-associated periodic syndromes (CAPS) are a rare, autoinflammatory disease group that generally has autosomal dominant inheritance.
Ilaris was previously approved for another periodic fever syndrome called Cryopyrin-Associated Periodic Syndromes (CAPS) and for active systemic juvenile idiopathic arthritis.
In early 2013, Sobi announced that the US Food and Drug Administration (FDA) had approved Kineret for the treatment of children and adults with neonatal-onset multisystem inflammatory disease (NOMID), the most severe form of Cryopyrin-Associated Periodic Syndromes (CAPS).
An interleukin-1 (IL-1) inhibitor, Anakinra (Kineret), has received a licence from the UK's Medicines and Healthcare Products Regulatory Agency for the treatment of cryopyrin-associated periodic syndromes in adults and children as young as eight months, it was reported yesterday.
Canakinumab (Ilaris) was approved in June 2009 for the treatment of a rare disorder, cryopyrin-associated periodic syndromes (CAPS).
In addition, the Kineret drug for the treatment of cryopyrin-associated periodic syndromes (CAPS) received orphan drug designation from the US Food and Drug Administration (FDA).
Already approved for cryopyrin-associated periodic syndromes, the anti-inflammatory interleukin-1 inhibitors rilonacept (Arcalyst) and canakinumab (Ilaris) are being studied both for acute gout and for prophylaxis.
Systemic JIA appears to be similar to other autoinflammatory syndromes in which IL-1 inhibition has been successful, including neonatal-onset multisystem inflammatory disease (NOMID) and cryopyrin-associated periodic syndromes (CAPS), said Dr.
Cryopyrin-Associated Periodic Syndromes (CAPS), Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome (FCAS)
Currently, ARCALYST is indicated in the US for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
Food and Drug Administration approved in February 2008 for the treatment of cryopyrin-associated periodic syndromes and Muckle-Wells syndrome in adults and children older than 12 years.
26 August 2010 - Biotech company Swedish Orphan Biovitrum (STO: BVT) said today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its product Kineret for the treatment of cryopyrin-associated periodic syndromes (CAPS).